A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.

Authors

null

Bo Yang

Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China

Bo Yang , Qi Xiong , Qi Song , Yaping Long , Gang Guo , Hongzhao Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

ChiCTR1900028022

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4567)

DOI

10.1200/JCO.2022.40.16_suppl.4567

Abstract #

4567

Poster Bd #

58

Abstract Disclosures

Similar Posters

First Author: Gong-Rang Chen

First Author: Akshat Saxena

First Author: Ke-Feng Ding